Comparison · NCT02032433-103f4faa
Extended-Release Naltrexone vs Buprenorphine-Naloxone: Other Drug Use Over Time, Stimulant, W24
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Extended-Release Naltrexone vs Buprenorphine-Naloxone: Other Drug Use Over Time, Stimulant, W24. Trial comparisons, record NCT02032433-103f4faa. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02032433-103f4faa
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0177 | 0.00757 | 0.0407 | wilson | |
| Risk in group 2 | 0.0105 | 0.00356 | 0.0303 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00721 | -0.015 | 0.0312 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.69 | 0.408 | 7.01 | log | |
| Odds ratio, group 1 over group 2 | 1.7 | 0.403 | 7.19 | log | |
| Number needed to treat, for one more participant with the outcome on Extended-Release Naltrexone than on Buprenorphine-Naloxone | 139 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Extended-Release Naltrexone | Extended-Release Naltrexone (Vivitrol)~Extended-Release Naltrexone: Extended-Release Naltrexone (Vivitrol®) | 5 | 283 | OG000 |
| Group 2 | Buprenorphine-Naloxone | Buprenorphine-Naloxone (Suboxone)~Buprenorphine-Naloxone: Buprenorphine-Naloxone (Suboxone®) | 3 | 287 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Other Drug Use Over Time, Stimulant, W24
- Description
- Other drug use over time measuring stimulant (cocaine, crack and amphetamine) at week 24
- Time frame
- week 24
- Population
Source ClinicalTrials.gov
Trial
- Title
- Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment
- NCT number
- NCT02032433
- Phases
- PHASE4
- Conditions
- Opioid Use Disorder
- Interventions
- Extended-Release Naltrexone, Buprenorphine-Naloxone
- Lead sponsor
- NYU Langone Health
- Results first posted
- 2018-01-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02032433?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02032433-103f4faa